Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma

ConclusionsApatinib might be effective in treating recurrent glioblastoma after chemoradiotherapy in terms of the overall response rate, but the efficacy is not durable and the clinical benefit is limited. The adverse effects of apatinib were acceptable.Clinical Trial RegistrationChiCTR-ONC-17013098, date of registration: 24 October, 2017.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research